Structure‐Based Design of a Macrocyclic PROTAC

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Constraining a molecule in its bioactive conformation via macrocyclization represents an attractive strategy to rationally design functional chemical probes. While this approach has been applied to enzyme inhibitors or receptor antagonists, to date it remains unprecedented for bifunctional molecules that bring proteins together, such as PROTAC degraders. Herein, we report the design and synthesis of a macrocyclic PROTAC by adding a cyclizing linker to the BET degrader MZ1. A co‐crystal structure of macroPROTAC‐1 bound in a ternary complex with VHL and the second bromodomain of Brd4 validated the rational design. Biophysical studies revealed enhanced discrimination between the second and the first bromodomains of BET proteins. Despite a 12‐fold loss of binary binding affinity for Brd4, macroPROTAC‐1 exhibited cellular activity comparable to MZ1. Our findings support macrocyclization as an advantageous strategy to enhance PROTAC degradation potency and selectivity between homologous targets.
Funding Information
  • European Research Council (ERC-2012-StG-311460 DrugE3CRLs)
  • H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2015-806323)
  • Wellcome Trust (100476/Z/12/Z, 094090/Z/10/Z)

This publication has 32 references indexed in Scilit: